Sevelamer nedsætter forekomsten af hypercalcæmi- tilfælde sammenlignet med patienter, der alene indtager kalcium- baserede fosfatbindemidler, formentlig fordi selve præparatet ikke indeholder kalcium.
Sevelamer decreases the incidence of hypercalcaemic episodes as compared to patients using calcium based phosphate binders alone, probably because the product itself does not contain calcium.